Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
批准号:
6666753
负责人:
DAVID A INGRAM
金额:
$12.8万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-27 至 2007-06-30
关键词:
BCL2 gene /protein apoptosis biological signal transduction cell cycle cell proliferation cell transplantation enzyme activity enzyme mechanism flow cytometry gene targeting genetic models genetically modified animals hematopoiesis laboratory mouse leukemia mitogen activated protein kinase myeloproliferative neoplasm neoplasm /cancer genetics neurofibromatosis neurofibromatosis type 1 protein /gene phosphatidylinositol 3 kinase protooncogene terminal nick end labeling
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutations in the NF1 tumor suppressor gene. Children with NF1 are predisposed to developing juvenile myelomonocytic leukemia (JMML). Neurofibromin, the protein product of NF1, is a negative regulator of p21ras activity. Though Nf1 -/- mice die in utero, mice reconstituted with Nf1 -/- fetal stem cells develop a myeloproliferative disease (MPD) similar to JMML in NF1 patients. However, alterations in p21ras signaling pathways in NF1 deficient cells responsible for MPD are unknown. Utilizing PI-3 kinase (PI3K) inhibitors, we have preliminary data implicating hyperactivation of the p21ras-PI3K pathway as responsible for the hyperproliferation and increased survival of Nf1 -/- cells. However, interpretation of results using PI3K inhibitors is limited because there are four classes of PI3K, and inhibitors inactivate all classes. Here we propose genetic experiments to determine whether hyperactivation of class IAPI3K alters the growth of Nf1 -/- hematopoietic cells. Our rationale for studying class IAPI3K in Nf1-/- cells is twofold. First, in contrast to other PI3Ks, all class IAPI3K catalytic subunits contain a p21ras-binding domain. Second, p21ras interacts with these subunits to augment kinase activity in vitro, and no evidence exists to show that p21ras augments the activity of other PI3K classes. Recently, a p85alpha (a regulatory subunit of class IAPI3K) knockout strain was generated which results in a 97% reduction in class IAPI3K activity in myeloid cells. We hypothesize that hyperactivation of the p21ras-class IAPI3K pathway, alters the proliferation and survival of Nf1 -/- hematopoietic cells and contributes to the progression of MPD in mice transplanted with Nf1 -/- cells. To test this hypothesis, we will conduct experiments utilizing a genetic intercross of Nf1 +/- and p85alpha knockout mice. The aims are: 1) To test whether hyperactivation of class IAPI3K contributes to MPD in mice reconstituted with Nf1 -/- stem cells by altering specific signaling pathways, 2) To examine how genetic inactivation of class IAPI3K alters the proliferation and survival of committed, multipotential, and primitive Nf1 +/+ and Nf1 -/- progenitor cells, 3) To examine how neurofibromin and class IAPI3K regulate cell cycle progression and survival of phenotypically defined hematopoietic cells in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8700545
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8015868
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8381830
-
项目类别:
-
资助金额:$36.22万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7000897
-
项目类别:
-
资助金额:$20.89万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8328652
-
项目类别:
-
资助金额:$36.32万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8533030
-
项目类别:
-
资助金额:$35.68万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:6866481
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:7192516
-
项目类别:
-
资助金额:$6.37万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:7038203
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:6506645
-
项目类别:
-
资助金额:$6.51万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:6738006
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7557436
-
项目类别:
-
资助金额:$20.28万
-
财政年份:--
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7678398
-
项目类别:
-
资助金额:$21.29万
-
财政年份:--
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7557442
-
项目类别:
-
资助金额:$21.76万
-
财政年份:--
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7911628
-
项目类别:
-
资助金额:$21.81万
-
财政年份:--
-
负责人:DAVID A INGRAM
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: